

Consolidated Financial Results for the Nine Months Ended December 31, 2025
<Under Japanese GAAP>

January 29, 2026

Company Name: SEKISUI CHEMICAL CO., LTD.
 Listing: Tokyo Stock Exchange
 Securities code: 4204 URL <https://www.sekisuichemical.com>
 Representative: Keita Kato, President
 Inquiries: Ikusuke Shimizu, Senior Managing Executive Officer
 TEL: +81-3- 6748-6467
 Scheduled date to commence dividend payments: -
 Preparation of supplementary material on quarterly financial results: Yes
 Holding of quarterly financial results briefing: Yes

(Figures rounded down to the nearest million yen)

1. Consolidated financial results for the nine months ended December 31, 2025 (from April 1, 2025 to December 31, 2025)

(1) Consolidated operating results (% figures represent changes from the same period of the previous year.)

	Net sales	Operating profit		Ordinary profit		Profit attributable to owners of parent		
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine months ended								
December 31, 2025	959,907	0.5	72,903	-5.8	80,730	-6.2	47,831	-30.2
December 31, 2024	955,342	3.4	77,359	17.5	86,097	18.2	68,495	17.2

Note: Comprehensive Income For the nine months ended December 31, 2025: 79,907 million yen (20.8%)

For the nine months ended December 31, 2024: 66,161 million yen (-16.8%)

	Profit attributable to owners of parent per share	Profit attributable to owners of parent per share (Diluted)
Nine months ended	yen	yen
December 31, 2025	115.62	—
December 31, 2024	163.73	—

(2) Consolidated financial position

	Total assets	Net assets	Equity to asset ratio
As of	Millions of yen	Millions of yen	%
December 31, 2025	1,403,667	854,817	58.7
March 31, 2025	1,330,786	835,366	60.7
Reference: Equity As of December 31, 2025:	824,283 million yen	As of March 31, 2025:	807,348 million yen

2. Cash dividends

(Date of Record)	Annual dividends per share				
	At the end of 1st Q	At the end of 2nd Q	At the end of 3rd Q	Fiscal year-end	Total
Fiscal year ended	yen	yen	yen	yen	yen
March 31, 2025	—	37.00	—	42.00	79.00
March 31, 2026	—	40.00	—		
March 31, 2026 (Forecast)				40.00	80.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated outlook for fiscal 2025 (April 1, 2025 to March 31, 2026)

(% figures represent changes from the same period of the previous year.)

	Net sales	Operating profit		Ordinary profit		Profit attributable to owners of parent	Profit attributable to owners of parent per share	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Full Year	1,327,900	2.3	110,000	1.9	112,000	0.9	72,000	-12.1

Note: Revisions to the forecast of consolidated earnings most recently announced: Yes

Notes:

(1) Significant changes in the scope of consolidation during the period: None
 Newly included: -
 Excluded: -

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes
 Note: For further details please refer to "(4) Notes to Consolidated Financial Statements (Accounting treatment specific to the preparation of quarterly consolidated financial statements)" on page 10 of the attached document "2. Consolidated Financial Statements and Notes."

(3) Changes in accounting policy, changes in accounting estimates, and restatement
 a) Changes in accounting policies due to revisions to accounting standards and other regulations: None
 b) Changes other than a): None
 c) Changes in accounting estimates: None
 d) Restatements: None

(4) Number of shares issued (common shares)

	As of December 31, 2025	430,507,285	As of March 31, 2025	444,507,285
a) Number of shares issued at the end of the period (including treasury shares):	As of December 31, 2025	23,042,602	As of March 31, 2025	26,963,200
b) Number of treasury shares at the end of the period:				
c) Average number of outstanding shares during the period (cumulative from the beginning of the fiscal year):	Nine months ended December 31, 2025	413,708,193	Nine months ended December 31, 2024	418,331,421

Note: Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

Note: Proper use of earnings forecasts, and other special matters

1. This report contains revisions to the consolidated forecasts for the fiscal year announced on October 30, 2025.
2. The earnings forecasts and other forward-looking statements presented in this report are based on information available at the time of its issue and on certain assumptions that the Group considers reasonable. Forward-looking statements in no capacity represent a guarantee that the Group will achieve the stated amounts. Various factors can cause actual results to differ materially from the forecasts. For important matters regarding the conditions associated with the assumptions of these forecasts and their appropriate use, please see "I. 3. Revision to the Consolidated Results Forecast and Other Forward-Looking Information" on page 3 of the Quarterly Financial Report (Attached document).

Note: The English-language quarterly financial statements have not been reviewed by certified public accountants or an audit firm.

I. Qualitative Information and Financial Review

1. Consolidated Business Results

(1) Group Overview (April 1, 2025 to December 31, 2025)

Net Sales: 959.9 billion yen (+0.5%), Operating Profit: 72.9 billion yen (-5.8%), Ordinary Profit: 80.7 billion yen (-6.2%), Profit Attributable to Owners of Parent: 47.8 billion yen (-30.2%)

In the first three quarters of fiscal 2025, the domestic housing market remained sluggish and global automobile production slumped, but market conditions in smartphones and semiconductors as well as aircraft were firm. As a result of increased sales of added-value products, the establishment of new pricing levels, and growth of high-end single-family homes and large-scale housing renovation projects, net sales increased year-on-year, reaching a record high.

Due to ongoing weakness in the EV market, recording of one-time expenses related to resin sales transactions in the first half of the fiscal year, impairment losses in the biorefinery business, and other factors, each level of profit decreased year-on-year.

(2) Overview by Business Segment (April 1, 2025 to December 31, 2025)

[Housing Company]

Net Sales: 395.0 billion yen (+2.4%), Operating Profit: 26.0 billion yen (+12.0%)

In the first three quarters of fiscal 2025, deteriorating consumer sentiment resulting from high prices, rising interest rates for home loans, and other factors caused the new construction market to slump, but sales were higher and profit increased substantially due to improved composition in the Housing business and higher unit prices for houses as well as an increase in orders in the Housing Renovation Business.

In the Housing business, net sales increased year-on-year as a result of our area-specific product strategy centered on high-end single-family homes and apartment buildings for urban areas such as Tokyo, Kinki, and Chubu, which contributed to an improved product composition and higher unit prices for houses. The value of orders received increased moderately year-on-year due to increased sales of high-end single-family homes and apartment buildings.

In the Housing Renovation business, orders for large-scale housing renovations increased due to a strengthened sales strategy and enhancement of regular inspections, and as a result, net sales increased year-on-year.

In the Residential business, the number of rental units under management in the Real Estate business increased steadily, resulting in a year-on-year increase in net sales.

[Urban Infrastructure and Environmental Products Company]

Net Sales: 172.6 billion yen (-1.0%), Operating Profit: 14.1 billion yen (-5.9%)

In the first three quarters of fiscal 2025, the domestic housing market remained sluggish while in the non-housing market, construction times at construction sites became prolonged due to labor shortages and other factors. Despite efforts to increase sales of prioritized products, expand overseas sales, maintain spreads, and control fixed costs, both sales and profits decreased.

In the Pipe Systems field, growth in sales volume slowed due to effects from the prolongation of construction periods in domestic non-housing markets as well as sluggish market conditions for chlorinated polyvinyl chloride (CPVC) in India.

In the Buildings and Infrastructures Composite Materials field, sales of fire protection and non-combustible

materials were firm, including new adoptions, and the use of synthetic lumber (FFU) railway sleepers increased, mainly in Europe. As a result, net sales increased year-on-year.

In the Infrastructure Renovation field, in the pipe renewal area, progress was made in inspection of aging pipes in Japan, and efforts were focused on increasing orders overseas. Orders for large-scale plant equipment projects were steadily acquired, and net sales increased year-on-year.

[High Performance Plastics Company]

Net Sales: 337.7 billion yen (+1.4%), Operating Profit: 44.0 billion yen (-3.1%)

In the first three quarters of fiscal 2025, net sales grew as a result of increased sales of high-performance interlayer films, etc. in the Mobility field. However, operating profit decreased due to the recording of one-time expenses related to resin sales transactions in Europe during the first half of the year.

In the Electronics field, the smart phone and semiconductor markets were firm and progress was made in acquiring new orders, resulting in a year-on-year increase in net sales.

In the Mobility field, some EV markets continued to slump, but sales of interlayer films used in head-up displays increased steadily and SEKISUI AEROSPACE CORPORATION reported firm demand for aircraft. As a result, net sales increased year-on-year.

In the Industrial field, new orders, including orders for sensors, care materials, and other products, were steadily acquired and sales of energy-saving and environmental contribution products, such as foam materials and tapes, increased, but demand for consumer goods and building materials remained stagnant, primarily in Europe and the U.S., resulting in a year-on-year decrease in net sales.

[Medical Business]

Net Sales: 68.0 billion yen (-6.8%), Operating Profit: 7.3 billion yen (-21.5%)

In the first three quarters of fiscal 2025, sales and profit decreased due to continued challenging conditions in overseas diagnostic demand.

In the Diagnostics business, demand for priority infectious disease diagnostic kits declined in the U.S. and there were negative effects from efforts to control healthcare costs in the Chinese market.

In the Pharmaceutical Sciences business, net sales increased year-on-year as a result of steady sales of key active pharmaceutical ingredients and orders in the contract drug development solutions business.

2. Overview of Financial Position as of the First Three Quarters of Fiscal 2025

Status of assets, liabilities, and net assets

Consolidated total assets as of the end of the first three quarters of fiscal 2025 were 1,403,667 million yen, an increase of 72,880 million yen from the end of the previous fiscal year.

[Assets]

Current assets were 709,188 million yen, an increase of 6,083 million yen from the end of the previous fiscal year. The main factors were an increase of 33,197 million yen in total inventories, an increase of 1,489 million yen in total trade receivables, and a decrease of 32,714 million yen in cash and deposits.

Fixed assets were 694,479 million yen, an increase of 66,797 million yen. The main factor was a 44,078 million yen increase in tangible fixed assets.

[Liabilities]

Total liabilities were 548,850 million yen, an increase of 53,430 million yen from the end of the previous fiscal year. The main factors were a decrease of 1,773 million yen in total trade payables of notes payable - trade, electronically recorded obligations - operating, and accounts payable - trade, an increase of 39,704 million yen in short-term borrowings, and the issuance of 20,000 million yen of corporate bonds.

[Net Assets]

Net assets were 854,817 million yen as of the end of the first three quarters of fiscal 2025, an increase of 19,450 million yen from the end of the previous fiscal year. The main factors were the recording of 47,831 million yen in profit attributable to owners of parent, 34,182 million yen in dividends paid, 25,967 million yen for purchase of treasury shares, an increase of 28,257 million yen in foreign currency translation adjustments, an increase of 2,982 million yen in valuation difference on available-for-sale securities, and a decrease of 2,316 million yen in remeasurements of defined benefit plans.

3. Revision to the Consolidated Results Forecast and Other Forward-Looking Information

With regard to the consolidated forecasts for fiscal 2025 as a whole, in light of market conditions, effects from foreign exchange rates, and other factors, we revised the forecast announced on October 30, 2025 as indicated in the table below.

Revision to Consolidated Results Forecast for the Fiscal Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026)

	Net Sales	Operating Profit	Ordinary Profit	Profit Attributable to Owners of Parent	Profit Attributable to Owners of Parent Per Share
Previous forecast (A) (announced on October 30, 2025)	Millions of yen 1,323,200	Millions of yen 110,000	Millions of yen 112,000	Millions of yen 72,000	Yen 174.04
Revised forecast (B)	1,327,900	110,000	112,000	72,000	176.70
Change (B-A)	4,700	0	0	0	—
Change (%)	0.4%	0.0%	0.0%	0.0%	—
Reference: Results for the previous year (FY2024)	1,297,754	107,951	110,958	81,925	195.93

There is no change to the annual dividend forecast in conjunction with the revision of the results forecast made at this time (the annual dividend for the fiscal year ending March 2026 is expected to be a total of 80 yen per share (a 40-yen interim dividend and a 40-yen year-end dividend).

2. Consolidated Financial Statements and Notes

(1) Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2025	As of December 31, 2025
Assets		
Current assets		
Cash and deposits	142,586	109,871
Notes receivable - trade	37,820	42,021
Accounts receivable - trade	167,960	165,249
Contract assets	1,758	1,811
Merchandise and finished goods	110,721	116,460
Land for sale in lots	69,187	77,614
Work in process	72,006	83,957
Raw materials and supplies	61,903	68,984
Advance payments to suppliers	5,274	6,681
Prepaid expenses	7,389	8,042
Short-term loans receivable	714	5,382
Other	26,465	23,589
Allowance for doubtful accounts	(686)	(480)
Total current assets	<u>703,104</u>	<u>709,188</u>
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	121,784	130,249
Machinery, equipment and vehicles, net	113,941	121,079
Land	86,517	87,847
Leased assets, net	21,294	21,258
Construction in progress	46,085	73,071
Other, net	14,245	14,443
Total property, plant and equipment	<u>403,870</u>	<u>447,949</u>
Intangible assets		
Goodwill	6,874	6,077
Software	16,915	31,688
Leased assets	64	280
Other	35,276	22,020
Total intangible assets	<u>59,131</u>	<u>60,067</u>
Investments and other assets		
Investment securities	105,102	113,453
Long-term loans receivable	923	952
Long-term prepaid expenses	1,757	2,636
Retirement benefit asset	35,575	35,968
Deferred tax assets	4,855	17,239
Other	17,179	17,002
Allowance for doubtful accounts	(714)	(789)
Total investments and other assets	<u>164,679</u>	<u>186,462</u>
Total non-current assets	<u>627,681</u>	<u>694,479</u>
Total assets	<u>1,330,786</u>	<u>1,403,667</u>

(Millions of yen)

As of March 31, 2025 As of December 31, 2025

Liabilities		
Current liabilities		
Notes payable - trade	413	610
Electronically recorded obligations - operating	15,782	16,092
Accounts payable - trade	107,356	105,076
Short-term borrowings	2,340	42,045
Current portion of bonds payable	—	10,000
Lease liabilities	5,422	5,571
Accrued expenses	44,254	40,925
Income taxes payable	16,870	12,899
Provision for bonuses	22,219	12,350
Provision for bonuses for directors (and other officers)	488	383
Provision for warranties for completed construction	2,209	1,904
Provision for share awards	108	104
Advances received	69,557	67,842
Other	52,977	69,702
Total current liabilities	340,002	385,509
Non-current liabilities		
Bonds payable	40,000	50,000
Long-term borrowings	46,042	40,686
Lease liabilities	17,025	17,406
Deferred tax liabilities	1,524	1,358
Retirement benefit liability	42,824	43,248
Provision for share awards	1,154	1,221
Other	6,845	9,421
Total non-current liabilities	155,417	163,341
Total liabilities	495,420	548,850
Net assets		
Shareholders' equity		
Share capital	100,002	100,002
Capital surplus	105,068	105,185
Retained earnings	544,799	530,861
Treasury shares	(50,082)	(48,236)
Total shareholders' equity	699,787	687,813
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	36,889	39,871
Deferred gains or losses on hedges	(0)	0
Revaluation reserve for land	319	306
Foreign currency translation adjustment	62,160	90,417
Remeasurements of defined benefit plans	8,190	5,873
Total accumulated other comprehensive income	107,560	136,469
Non-controlling interests	28,018	30,533
Total net assets	835,366	854,817
Total liabilities and net assets	1,330,786	1,403,667

(2) Consolidated Statements of Income and Statement of Comprehensive Income

(Consolidated Statements of Income)

Nine months ended December 31, 2025

(Millions of yen)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Net sales	955,342	959,907
Cost of sales	644,936	648,734
Gross profit	310,405	311,172
Selling, general and administrative expenses	233,046	238,269
Operating profit	77,359	72,903
Non-operating income		
Interest income	1,572	1,626
Dividend income	3,218	3,357
Share of profit of entities accounted for using equity method	528	483
Foreign exchange gains	3,947	3,156
Miscellaneous income	2,788	2,742
Total non-operating income	12,055	11,365
Non-operating expenses		
Interest expenses	749	990
Loss on tax purpose reduction entry of non-current assets	941	392
Miscellaneous expenses	1,626	2,156
Total non-operating expenses	3,317	3,538
Ordinary profit	86,097	80,730
Extraordinary income		
Gain on sale of investment securities	14,499	5,420
Gain on sale of non-current assets	—	63
Total extraordinary income	14,499	5,483
Extraordinary losses		
Impairment losses	187	17,755
Loss on sale and retirement of non-current assets	1,429	1,870
Loss on valuation of investment securities	245	612
Total extraordinary losses	1,862	20,238
Profit before income taxes	98,734	65,976
Income taxes	28,619	16,512
Profit	70,115	49,463
Profit attributable to non-controlling interests	1,620	1,632
Profit attributable to owners of parent	68,495	47,831

Third Quarter, Fiscal 2025

(Millions of yen)

	Third Quarter Fiscal 2024 (from October 1, 2024 to December 31, 2024)	Third Quarter Fiscal 2025 (from October 1, 2025 to December 31, 2025)
Net sales	326,287	330,110
Cost of sales	218,684	221,887
Gross profit	107,603	108,222
Selling, general and administrative expenses	78,966	80,766
Operating profit	28,636	27,455
Non-operating income		
Interest income	550	538
Dividend income	536	622
Share of profit of entities accounted for using equity method	443	—
Foreign exchange gains	8,058	4,188
Miscellaneous income	1,341	1,287
Total non-operating income	10,929	6,635
Non-operating expenses		
Interest expenses	218	391
Loss on tax purpose reduction entry of non-current assets	941	133
Share of loss of entities accounted for using equity method	—	752
Miscellaneous expenses	450	1,034
Total non-operating expenses	1,610	2,312
Ordinary profit	37,955	31,778
Extraordinary income		
Gain on sale of investment securities	25	5,374
Gain on sale of non-current assets	—	16
Total extraordinary income	25	5,391
Extraordinary losses		
Impairment losses	187	16,027
Loss on sale and retirement of non-current assets	545	956
Loss on valuation of investment securities	3	112
Total extraordinary losses	736	17,096
Profit before income taxes	37,243	20,073
Income taxes	11,087	3,359
Profit	26,155	16,714
Profit attributable to non-controlling interests	586	606
Profit attributable to owners of parent	25,569	16,108

(Consolidated Statement of Comprehensive Income)

(Millions of yen)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Profit	70,115	49,463
Other comprehensive income		
Valuation difference on available-for-sale securities	(7,622)	3,105
Deferred gains or losses on hedges	(0)	0
Foreign currency translation adjustment	7,292	29,811
Remeasurements of defined benefit plans, net of tax	(3,544)	(2,347)
Share of other comprehensive income of entities accounted for using equity method	(79)	(126)
Total other comprehensive income	(3,953)	30,443
Comprehensive income	66,161	79,907
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	64,291	76,740
Comprehensive income attributable to non-controlling interests	1,869	3,167

(3) Consolidated Statement of Cash Flows

(Millions of yen)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Cash flows from operating activities		
Profit before income taxes	98,734	65,976
Depreciation	38,831	41,966
Amortization of goodwill	1,046	944
Impairment losses	187	17,755
Loss on retirement of non-current assets	1,417	1,847
Loss (gain) on sale of non-current assets	12	(40)
Increase or decrease in retirement benefit asset and liability	(2,221)	(3,374)
Loss (gain) on sale of investment securities	(14,499)	(5,420)
Loss (gain) on valuation of investment securities	245	612
Increase (decrease) in provision for bonuses	(7,794)	(9,980)
Interest and dividend income	(4,790)	(4,983)
Interest expenses	749	990
Share of loss (profit) of entities accounted for using equity method	(528)	(483)
Decrease (increase) in accounts receivable - trade, and contract assets	7,102	7,843
Decrease (increase) in inventories	(22,064)	(24,268)
Increase (decrease) in trade payables	(2,444)	(12,822)
Increase (decrease) in advances received	11,137	(2,242)
Other, net	(3,958)	4,977
Subtotal	101,162	79,297
Interest and dividends received	5,000	5,157
Interest paid	(811)	(1,006)
Income taxes refund	2,364	619
Income taxes paid	(38,976)	(31,306)
Net cash provided by (used in) operating activities	68,738	52,761
Cash flows from investing activities		
Purchase of property, plant and equipment	(39,753)	(71,697)
Proceeds from sale of property, plant and equipment	935	681
Payments into time deposits	(15,342)	(9,393)
Proceeds from withdrawal of time deposits	13,074	27,253
Purchase of investment securities	(1,112)	(5,646)
Purchase of shares of subsidiaries	(105)	—
Proceeds from sale and redemption of investment securities	15,913	6,755
Purchase of intangible assets	(9,902)	(10,341)
Decrease (increase) in short-term loans receivable	330	(4,668)
Other, net	1,150	2,657
Net cash provided by (used in) investing activities	(34,810)	(64,399)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	578	24,403
Repayments of lease liabilities	(4,186)	(4,638)
Proceeds from long-term borrowings	398	10,022
Repayments of long-term borrowings	(9,673)	(316)
Proceeds from issuance of bonds	—	19,939
Redemption of bonds	(30)	—
Dividends paid	(31,952)	(34,224)
Dividends paid to non-controlling interests	(967)	(1,316)
Proceeds from share issuance to non-controlling shareholders	—	406
Purchase of treasury shares	(8,921)	(25,968)
Purchase of shares of subsidiaries not resulting in change in scope of consolidation	(41)	(191)
Other, net	139	127
Net cash provided by (used in) financing activities	(54,657)	(11,756)
Effect of exchange rate change on cash and cash equivalents	1,655	7,537
Net increase (decrease) in cash and cash equivalents	(19,073)	(15,857)
Cash and cash equivalents at beginning of period	126,367	120,895
Increase in cash and cash equivalents resulting from inclusion of subsidiaries in consolidation	60	738
Cash and cash equivalents at end of period	107,354	105,777

(4) Notes to Consolidated Financial Statements

(The premise of a going concern)

Not applicable.

(Significant Change in Shareholder Equity)

Not applicable.

(Accounting treatment specific to the preparation of quarterly consolidated financial statements)

(Calculation of tax expense)

Tax expenses are calculated by reasonably estimating the effective tax rate after applying tax effect accounting to profit before income taxes for the fiscal year, including the third quarter of the current fiscal year, and multiplying profit before income taxes (quarterly) by the estimated effective tax rate. However, if the calculation of tax expenses using such estimated effective tax rate would significantly lack rationality, tax expenses are calculated using the statutory tax rate. Income taxes - deferred are included in income taxes.

(Segment Information)

Nine months ended December 31, 2024 (from April 1, 2024 to December 31, 2024)

1. Information on the amounts of net sales, and profit or loss, for each reportable segment and information on disaggregation of revenue

(Millions of yen)

	Reportable Segments					Other (Notes 1,2)	Total
	Housing (Note 1)	UIEP	HPP	Medical	Total		
Net Sales							
Japan	384,564	135,360	85,683	35,236	640,845	1,744	642,589
North America	—	2,243	83,180	17,358	102,782	—	102,782
Europe	—	5,110	62,101	8,293	75,505	—	75,505
China	—	2,853	55,412	10,098	68,364	1,369	69,733
Asia	1,014	16,770	37,953	1,643	57,382	32	57,414
Others	—	1,934	5,011	370	7,316	—	7,316
Net sales to external customers	385,579	164,273	329,341	73,001	952,196	3,146	955,342
Intersegment sales or transfers	74	10,002	3,770	—	13,847	1,922	15,770
Total	385,653	174,275	333,112	73,001	966,044	5,068	971,112
Segment profit (loss)	23,274	15,024	45,461	9,296	93,056	(8,849)	84,206

(Note 1) Net sales in “Housing” include 33,409 million yen that does not correspond to revenue from contracts with customers under “Japan.”

Net sales in “Other” include 792 million yen that does not correspond to revenue from contracts with customers under “Japan.”

(Note 2) “Other” represents segments other than the reportable segments and includes provision of services and manufacturing and sales of film-type lithium-ion batteries and products not included in the reportable segments.

2. Difference between the total amount of profit or loss of the reportable segments and the amount recorded in the quarterly consolidated statement of income, and descriptions on such difference (matters on difference adjustment)

(Millions of yen)

Profit	Amount
Reportable segment total	93,056
Profit (loss) in “Other”	(8,849)
Intersegment eliminations	(142)
Corporate expenses (Note)	(6,704)
Operating profit in the quarterly consolidated statement of income	77,359

(Note) Corporate expenses are mainly general and administrative expenses not attributable to each reportable segment.

Nine months ended December 31, 2025 (from April 1, 2025 to December 31, 2025)

1. Information on the amounts of net sales, and profit or loss, for each reportable segment and information on disaggregation of revenue

	Reportable Segments					Other (Notes 1,2)	Total
	Housing (Note 1)	UIEP	HPP	Medical	Total		
Net Sales							
Japan	393,722	136,394	86,420	36,353	652,891	1,608	654,499
North America	—	2,518	85,571	15,128	103,218	—	103,218
Europe	—	6,030	58,581	6,956	71,568	—	71,568
China	—	2,348	59,902	7,706	69,957	252	70,210
Asia	1,051	11,870	38,028	1,662	52,612	53	52,666
Others	—	1,888	5,646	209	7,744	—	7,744
Net sales to external customers	394,774	161,050	334,152	68,016	957,992	1,914	959,907
Intersegment sales or transfers	284	11,566	3,639	—	15,490	3,525	19,015
Total	395,058	172,616	337,791	68,016	973,483	5,440	978,923
Segment profit (loss)	26,067	14,133	44,049	7,301	91,551	(9,779)	81,772

(Note 1) Net sales in “Housing” include 34,573 million yen that does not correspond to revenue from contracts with customers under “Japan.”

Net sales in “Other” include 698 million yen that does not correspond to revenue from contracts with customers under “Japan.”

(Note 2) “Other” represents segments other than the reportable segments and includes provision of services and manufacturing and sales of film-type lithium-ion batteries and products not included in the reportable segments.

2. Difference between the total amount of profit or loss of the reportable segments and the amount recorded in the quarterly consolidated statement of income, and descriptions on such difference (matters on difference adjustment)

		(Millions of yen)
Profit		Amount
Reportable segment total		91,551
Profit (loss) in “Other”		(9,779)
Intersegment eliminations		(439)
Corporate expenses (Note)		(8,429)
Operating profit in the quarterly consolidated statement of income		72,903

(Note) Corporate expenses are mainly general and administrative expenses not attributable to each reportable segment.